Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2016, Vol. 36 Issue (2): 90-95    DOI: 10.13523/j.cb.20160213
    
Progress in the Application of Non-immunoglobulin Scaffolds
LI Geng, LIU Xiao-zhi, WANG Zhi-ming, GAO Jian
State Key Laboratory of Antibody Research & Development;New Drug Research and Development Company Ltd., North China Pharmaceutical Corporation, Shijiazhuang 050015, China
Download: HTML   PDF(476KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Compared with the antibody drugs, the non-immune globulin scaffolds with a small molecular weight, do not need to be modified after translation, usually lack disulfide bonds, and can undergo straightforward multimerization. In recent years, the development of non-immune globulin scaffolds have reached more than 20 different types, such as Adhirons, Alphabodies, Centyrins, Pronectins, Repebodies, Affimers, and Obodies. 102 proteins have been specifically targeted by 139 different non-Ig scaffold binders. These non-immune globulin scaffolds are used for the treatment and diagnosis of cancer and inflammatory diseases, and there are more than 10 types of non-immune globulin scaffolds have been used in clinical trials. Recently, non-immune globulin scaffolds have also been used in research as structure determination chaperones, which are used in the study for intracellular monitoring of post-translational modifications or as an alternative to antibodiesfor microscopy, flow cytometry, and Western blotting, and so on.



Key wordsBiotechnology      Antibody alternatives      Non-immunoglobulin scaffolds     
Received: 11 September 2015      Published: 19 November 2015
ZTFLH:  Q819  
Cite this article:

LI Geng, LIU Xiao-zhi, WANG Zhi-ming, GAO Jian. Progress in the Application of Non-immunoglobulin Scaffolds. China Biotechnology, 2016, 36(2): 90-95.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20160213     OR     https://manu60.magtech.com.cn/biotech/Y2016/V36/I2/90

[1] Koerber J T,Hornsby M J,Wells J A.An improved single-chain Fab platform for efficient display and recombinant expression.Journal of Molecular Biology,2015,427(2):576-586.
[2] Skrlec K,Strukelj B,Berlec A.Non-immunoglobulin scaffolds:a focus on their targets.Trends in Biotechnology,2015,33(7):408-418.
[3] Levisson M,Spruijt R B,Winkel I N,et al.Phage display of engineered binding proteins.Methods in Molecular Biology,2014,1129:211-229.
[4] Lee Y,Lee J J,Kim S,et al.Dissecting the critical factors for thermodynamic stability of modular proteins using molecular modeling approach.PloS One,2014,9(5):e98243.
[5] Lin H,Zhou J,Shen L,et al.Biotin-conjugated anti-CD44 antibody-avidin binding system for the improvement of chondrocyte adhesion to scaffolds.Journal of Biomedical Materials Research Part A,2014,102(4):1140-1148.
[6] Helma J,Cardoso M C,Muyldermans S,et al.Nanobodies and recombinant binders in cell biology.The Journal of Cell Biology,2015,209(5):633-644.
[7] Zielonka S,Empting M,Grzeschik J,et al.Structural insights and biomedical potential of IgNAR scaffolds from sharks.mAbs,2015,7(1):15-25.
[8] Liang S I,McFarland J M,Rabuka D,et al.A modular approach for assembling aldehyde-tagged proteins on DNA scaffolds.Journal of the American Chemical Society,2014,136(31):10850-10853.
[9] Maltezos A,Platis D,Vlachakis D,et al.Design,synthesis and application of benzyl-sulfonate biomimetic affinity adsorbents for monoclonal antibody purification from transgenic corn.Journal of Molecular Recognition,2014,27(1):19-31.

[1] LIU Xu-xia,YANG An-ke. An Analysis of the U.S. SECURE Rule and Its Enlightenment to China[J]. China Biotechnology, 2021, 41(9): 126-135.
[2] HU Yuan-lei,CHEN Yan-cheng,PU Run,YAO Wei-hao,ZHANG Hong-xiang. Bio-tech Startup Incubation Best Practice in the United Kingdom and Suggestion[J]. China Biotechnology, 2021, 41(4): 100-105.
[3] WU Han-rong,WANG Ying,HUANG Ying-ming,LI Dong-xue,LI Zhi-fei,FANG Zi-han,FAN Lin. Promote the Innovation and Transformation of Biotechnology by Base Platform[J]. China Biotechnology, 2021, 41(12): 141-147.
[4] WU Han-rong,WANG Ying,YANG Li,GE Yao,FAN Ling. Current Situation and Development Suggestions of China’s Biotechnology Base Platform[J]. China Biotechnology, 2021, 41(11): 119-123.
[5] WU Han-rong,WANG Ying,LI Su-ning,SANG Xiao-dong,FAN Ling. Policy Research on the Construction of Biotechnology Base Platforms in China[J]. China Biotechnology, 2021, 41(10): 127-131.
[6] WANG Xiao-li. The Age of Biosecurity: New Biotechnology Revolution and National Biosecurity Governance[J]. China Biotechnology, 2020, 40(9): 95-109.
[7] SONG Yi-mei,JIA Xiu-wei,LI Shu-biao,GAO Cui-juan. Industrial Microorganism of Yarrowia lipolytica and Its Industrial Amplicaiton[J]. China Biotechnology, 2020, 40(9): 77-86.
[8] HU Yuan-lei,YAO Wei-hao,PU Run,ZHANG Hong-xiang. Bio-tech Startup Incubation Best Practice in the United States[J]. China Biotechnology, 2019, 39(12): 103-109.
[9] Ping ZHAO,Bo ZHANG,Xue-zhao WANG. Patent Situation Analysis in Agricultural Biotechnology Field[J]. China Biotechnology, 2018, 38(8): 100-107.
[10] Fang CHEN,Yun-wei CHEN,Chen-jun DING,Ying ZHENG,Xiao-yan WU,Dan-dan LUO,Qiu-wei ZHAO,Bo YU. A Study on the Trends of Biotechnology Development in Countries along the Belt and Road[J]. China Biotechnology, 2018, 38(1): 1-14.
[11] SHEN Ping, WU Yu-hua, LIANG Jin-gang, LU Xin, ZHANG Qiu-yan, WANG Hao-qian, LIU Peng-cheng. The Overview in Development and Application of Genetically Modifed Crops[J]. China Biotechnology, 2017, 37(1): 119-128.
[12] CHEN Fang, DING Chen-jun, CHEN Yun-wei, ZHENG Ying, DENG Yong, XU Ping, YU Jian-rong, WU Lin-huan, MA Jun-cai, ZENG Yan, LIU Bin. A Study on the Trend and Prospective of Industrial Biotechnology in China[J]. China Biotechnology, 2016, 36(5): 1-11.
[13] WANG Kai, ZHANG Wei, LI Shi-weng. Study and Application of Phytase[J]. China Biotechnology, 2015, 35(9): 85-93.
[14] GAO Jiao-qi, HAN Xi-tong, KONG Liang, YUAN Wen-jie, WANG Na, BAI Feng-wu. Application Progress of Kluyveromyces marxianus in the Industrial Biotechnology[J]. China Biotechnology, 2014, 34(2): 109-117.
[15] WU Xue-mei, QU Kai. Problems and Solutions in the Drafting of Biotechnological Patents[J]. China Biotechnology, 2013, 33(12): 127-132.